^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Meiyouheng (becotatug vedotin)

    i
    Other names: MRG003, MRG-003, MRG 003
    Company:
    Lepu Med
    Drug class:
    Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    Related drugs:
    4d
    MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, West China Hospital
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    4d
    A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, West China Hospital
    New P2 trial • Checkpoint inhibition
    |
    Anniko (penpulimab-kcqx) • Meiyouheng (becotatug vedotin) • Yidafan (ivonescimab) • becotarug (JMT101)
    6d
    Efficacy and Safety of Becotatug Vedotin (EGFR ADC) plus Pucotenlimab and Cisplatin as Neoadjuvant Therapy for LA-HNSCC (ChiCTR2600115972)
    P=N/A, N=30, Not yet recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    17d
    Magic-C002: A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=446, Recruiting, Shanghai Miracogen Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • docetaxel • capecitabine • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    28d
    MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • Meiyouheng (becotatug vedotin)
    2ms
    Pembrolizumab + MRGOO3 as Neoadjuvant in NPC (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    Keytruda (pembrolizumab) • Meiyouheng (becotatug vedotin)
    3ms
    MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC (clinicaltrials.gov)
    P2, N=60, Recruiting, Fudan University
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    5ms
    IDEAL: Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck (clinicaltrials.gov)
    P2, N=106, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou | Initiation date: Jun 2025 --> Oct 2025
    Trial initiation date
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    7ms
    A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (clinicaltrials.gov)
    P2, N=116, Recruiting, Shanghai Miracogen Inc. | Trial completion date: Sep 2023 --> Dec 2026 | Trial primary completion date: Jan 2023 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    9ms
    Magic-C002: A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=446, Not yet recruiting, Shanghai Miracogen Inc.
    New P3 trial
    |
    gemcitabine • docetaxel • capecitabine • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    9ms
    IDEAL: Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck (clinicaltrials.gov)
    P2, N=106, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    3years
    A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Shanghai Miracogen Inc.
    New P1/2 trial • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR positive
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)